Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Updated trial data show a meaningful survival edge for a targeted prostate cancer combo. In the phase 3 CAPItello-281 trial, adding capivasertib to abiraterone and ADT extended median overall survival by nearly 11 months compared to placebo in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer. The FDA approved this combination in June 2026, marking it the first targeted therapy for this patient population.
Updated data from the phase 3 CAPItello-281 trial continue to support the survival benefit of capivasertib (Truqap) added to abiraterone and androgen deprivation therapy (ADT) in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). With approximately 17 months of additional follow-up, the capivasertib arm showed a median overall survival (OS) of 57.4 months versus 46.5 months in the placebo arm — a nearly 11-month difference. Radiographic progression-free survival also favored capivasertib at 35.5 vs. 26.0 months.
Importantly, the safety profile remained manageable over time. The most common side effects — diarrhea, hyperglycemia, and rash — tended to emerge early in treatment and did not worsen with longer exposure. Clinicians can use a grade-based approach to manage these effects, including metformin for early hyperglycemia and corticosteroids for rash.
Key Takeaways:
Why it matters: The FDA approved capivasertib plus abiraterone in June 2026 as the first targeted treatment for PTEN-deficient mHSPC. These updated results reinforce its clinical value and help oncologists better understand long-term tolerability — critical for a patient population that may be on therapy for years.
